Please try another search
Omega Therapeutics, Inc. is a clinical-stage biotechnology company. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, which are programmable and modular epigenetic medicines, called omega epigenomic controllers (OECs), to target EpiZips for precision epigenomic control. Its pipeline consists of early-stage programs that span oncology, multigenic diseases including immunology, regenerative medicine, and select monogenic diseases. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunology, regenerative medicine and select monogenic diseases.
Name | Age | Since | Title |
---|---|---|---|
Richard A. Young | 68 | 2017 | Independent Director & Scientific Advisor |
Elliott M. Levy | 62 | 2021 | Independent Director |
Rainer J. Boehm | 62 | 2022 | Independent Director |
Mahesh Karande | 49 | 2019 | President, CEO & Board Director |
Rudolf Jaenisch | - | - | Scientific Advisor |
Luke M. Beshar | 65 | 2021 | Independent Director |
Michelle C. Werner | 48 | 2023 | Independent Director |
Christian S. Schade | 63 | 2023 | Independent Chairman of Board |
John D. Mendlein | 64 | 2020 | Independent Director |
Mary T. Szela | 60 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review